Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth

Cancer Cell

Volumn 11, Issue 1, 2007, Pages 53-67

  Pan, Qi ^a   Chanthery, Yvan ^a   Liang, Wei Ching ^a   Stawicki, Scott ^a   Mak, Judy ^a   Rathore, Nisha ^a   Tong, Raymond K ^a   Kowalski, Joe ^a   Yee, Sharon Fong ^a   Pacheco, Glenn ^a   Ross, Sarajane ^a   Cheng, Zhiyong ^a   Le Couter, Jennifer ^a   Plowman, Greg ^a   Peale, Franklin ^a   Koch, Alexander W ^a   Wu, Yan ^a   Bagri, Anil ^a   Tessier Lavigne, Marc ^a   Watts, Ryan J ^a  

^a GENENTECH INC   (United States)

Author keywords

CELLCYCLE

Indexed keywords

MONOCLONAL ANTIBODY; NEUROPILIN 1; PLEXIN; SEMAPHORIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; NONHUMAN; PERICYTE; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 33845991161     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.10.018     Document Type: Article

References (53)

1. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., and Mercurio A.M. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61 (2001) 5736-5740
2. Baluk P., Hashizume H., and McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15 (2005) 102-111
3. Benjamin L.E., Hemo I., and Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125 (1998) 1591-1598
4. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 (2003) 1287-1295
5. Bielenberg D.R., Pettaway C.A., Takashima S., and Klagsbrun M. Neuropilins in neoplasms: Expression, regulation, and function. Exp. Cell Res. 312 (2006) 584-593
6. Cai H., and Reed R.R. Cloning and characterization of neuropilin-1-interacting protein: A PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J. Neurosci. 19 (1999) 6519-6527
7. Carmeliet P., and Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 436 (2005) 193-200
8. Chen J., Somanath P.R., Razorenova O., Chen W.S., Hay N., Bornstein P., and Byzova T.V. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 11 (2005) 1188-1196
9. Cross M.J., Dixelius J., Matsumoto T., and Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28 (2003) 488-494
10. De Vries L., Lou X., Zhao G., Zheng B., and Farquhar M.G. GIPC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-GAIP. Proc. Natl. Acad. Sci. USA 95 (1998) 12340-12345
11. Dorrell M.I., and Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Prog. Retin. Eye Res. 25 (2006) 277-295
12. Dougher M., and Terman B.I. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18 (1999) 1619-1627
13. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., and Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18 (2004) 338-340
14. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
15. Gerber H.P., Dixit V., and Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273 (1998) 13313-13316
16. Gerhardt H., Golding M., Fruttiger M., Ruhrberg C., Lundkvist A., Abramsson A., Jeltsch M., Mitchell C., Alitalo K., Shima D., and Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161 (2003) 1163-1177
17. Gerhardt H., Ruhrberg C., Abramsson A., Fujisawa H., Shima D., and Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev. Dyn. 231 (2004) 503-509
18. Gray M.J., Wey J.S., Belcheva A., McCarty M.F., Trevino J.G., Evans D.B., Ellis L.M., and Gallick G.E. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res. 65 (2005) 3664-3670
19. Gu C., Limberg B.J., Whitaker G.B., Perman B., Leahy D.J., Rosenbaum J.S., Ginty D.D., and Kolodkin A.L. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J. Biol. Chem. 277 (2002) 18069-18076
20. Gu C., Rodriguez E.R., Reimert D.V., Shu T., Fritzsch B., Richards L.J., Kolodkin A.L., and Ginty D.D. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev. Cell 5 (2003) 45-57
21. Hansel D.E., Wilentz R.E., Yeo C.J., Schulick R.D., Montgomery E., and Maitra A. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am. J. Surg. Pathol. 28 (2004) 347-356
22. He Z., and Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90 (1997) 739-751
23. Herzog Y., Kalcheim C., Kahane N., Reshef R., and Neufeld G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev. 109 (2001) 115-119
24. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., Hu-Lowe D.D., Shalinsky D.R., Thurston G., Yancopoulos G.D., and McDonald D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165 (2004) 35-52
25. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3 (2006) 24-40
26. Jia H., Bagherzadeh A., Hartzoulakis B., Jarvis A., Lohr M., Shaikh S., Aqil R., Cheng L., Tickner M., Esposito D., et al. Characterisation of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signalling. J Biol Chem. 281 (2006) 13493-13502
27. Kamiya T., Kawakami T., Abe Y., Nishi M., Onoda N., Miyazaki N., Oida Y., Yamazaki H., Ueyama Y., and Nakamura M. The preserved expression of neuropilin (NRP) 1 contributes to a better prognosis in colon cancer. Oncol. Rep. 15 (2006) 369-373
28. Kawakami T., Tokunaga T., Hatanaka H., Kijima H., Yamazaki H., Abe Y., Osamura Y., Inoue H., Ueyama Y., and Nakamura M. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 95 (2002) 2196-2201
29. Kawasaki T., Kitsukawa T., Bekku Y., Matsuda Y., Sanbo M., Yagi T., and Fujisawa H. A requirement for neuropilin-1 in embryonic vessel formation. Development 126 (1999) 4895-4902
30. Kerbel R.S., Yu J., Tran J., Man S., Viloria-Petit A., Klement G., Coomber B.L., and Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20 (2001) 79-86
31. Klagsbrun M., Takashima S., and Mamluk R. The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 515 (2002) 33-48
32. Kolodkin A.L., Levengood D.V., Rowe E.G., Tai Y.T., Giger R.J., and Ginty D.D. Neuropilin is a semaphorin III receptor. Cell 90 (1997) 753-762
33. Latil A., Bieche I., Pesche S., Valeri A., Fournier G., Cussenot O., and Lidereau R. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int. J. Cancer 89 (2000) 167-171
34. Liang W.C., Wu X., Peale F.V., Lee C.V., Meng Y.G., Gutierrez J., Fu L., Malik A.K., Gerber H.P., Ferrara N., and Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281 (2006) 951-961
35. Liang W.-C., Dennis M.S., Stawicki S., Chanthery Y., Pan Q., Chen Y., Eigenbrot C., Yin J., Koch A.W., Wu X., et al. Function blocking antibodies to Neuropilin-1 generated from a designed human synthetic antibody phage library. J. Mol. Biol. (2007) 10.1016/j.jmb.2006.11.021 in press
36. Liu W., Parikh A.A., Stoeltzing O., Fan F., McCarty M.F., Wey J., Hicklin D.J., and Ellis L.M. Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. Cytokine 32 (2005) 206-212
37. Miao H.Q., Soker S., Feiner L., Alonso J.L., Raper J.A., and Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165. J. Cell Biol. 146 (1999) 233-242
38. Miao H.Q., Lee P., Lin H., Soker S., and Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J. 14 (2000) 2532-2539
39. Murga M., Fernandez-Capetillo O., and Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood. 105 (2005) 1992-1999 10.1182/blood-2004-07-2598 Published online November 2, 2004
40. Nakatsu M.N., Sainson R.C., Aoto J.N., Taylor K.L., Aitkenhead M., Perez-del-Pulgar S., Carpenter P.M., and Hughes C.C. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: The role of fibroblasts and Angiopoietin-1. Microvasc. Res. 66 (2003) 102-112
41. Rousseau S., Houle F., Landry J., and Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15 (1997) 2169-2177
42. Serini G., Valdembri D., Zanivan S., Morterra G., Burkhardt C., Caccavari F., Zammataro L., Primo L., Tamagnone L., Logan M., et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424 (2003) 391-397
43. Six I., Kureishi Y., Luo Z., and Walsh K. Akt signaling mediates VEGF/VPF vascular permeability in vivo. FEBS Lett. 532 (2002) 67-69
44. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
45. Soker S., Miao H.Q., Nomi M., Takashima S., and Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85 (2002) 357-368
46. Takahashi T., Ueno H., and Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18 (1999) 2221-2230
47. Takahashi T., Yamaguchi S., Chida K., and Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 20 (2001) 2768-2778
48. Takashima S., Kitakaze M., Asakura M., Asanuma H., Sanada S., Tashiro F., Niwa H., Miyazaki Ji J., Hirota S., Kitamura Y., et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc. Natl. Acad. Sci. USA 99 (2002) 3657-3662
49. Vanveldhuizen P.J., Zulfiqar M., Banerjee S., Cherian R., Saxena N.K., Rabe A., Thrasher J.B., and Banerjee S.K. Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol. Rep. 10 (2003) 1067-1071
50. Wang L., Zeng H., Wang P., Soker S., and Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J. Biol. Chem. 278 (2003) 48848-48860
51. Wang L., Mukhopadhyay D., and Xu X. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J. 20 (2006) 1513-1515
52. Wey J.S., Gray M.J., Fan F., Belcheva A., McCarty M.F., Stoeltzing O., Somcio R., Liu W., Evans D.B., Klagsbrun M., et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br. J. Cancer 93 (2005) 233-241
53. Yuan L., Moyon D., Pardanaud L., Breant C., Karkkainen M.J., Alitalo K., and Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129 (2002) 4797-4806